# Specification Quality Checklist: Allergies and Clinical-Content Governance

**Purpose**: Review Feature 011 requirements quality before Product Owner approval and subsequent lifecycle work.
**Created**: 2026-10-01 (Africa/Cairo)
**Feature**: [spec.md](../spec.md)
**Review ownership**: Agent draft-quality review only; Product Owner/domain approval remains pending.
**Marker semantics**: A checked item means the specification-quality criterion is satisfied, not that implementation, clinical content, release or an OPEN gate is approved. This is the Specify-generated quality checklist; no separate Checklist, Clarify or Analyze command was run.

## Content Quality

- [x] CHK001 No implementation choices (languages, frameworks, new endpoint/schema designs): §§5–7 preserve canonical ownership and the requested operation identifiers; physical design is explicitly deferred.
- [x] CHK002 Focused on user value and business needs: §1 problem and J-01–04 address provenance, independent governance and unavailable content.
- [x] CHK003 Written for non-technical stakeholders: journeys and outcomes describe observable reporting/review/publication behavior; canonical identifiers supply required traceability.
- [x] CHK004 All mandatory sections completed: all 15 headings from the resolved SHIFAA override are retained; genuine policy gaps are explicitly labeled, and implementation-only detail is reserved for Plan.

## Requirement Completeness

- [x] CHK005 No clarification markers remain: exactly three remain in §14 (Q1–Q3).
- [x] CHK006 Requirements are testable and unambiguous: the frozen invariants are testable, but allergy initial/transition/field policy, reviewer/clinic-read authority and temporal/content selection depend on Q1–Q3.
- [x] CHK007 Success criteria are measurable: SC-001–07 specify exact preservation/parity/denial/one-effect and inherited responsiveness targets.
- [x] CHK008 Success criteria are technology-agnostic: outcomes concern readers, governed publication, recovery and response time; no chosen stack or persistence mechanism.
- [x] CHK009 All acceptance scenarios are defined: AC-02, AC-08, AC-09 and AC-13 explicitly await complete policy matrices; no policy was guessed to mark this item complete.
- [x] CHK010 Edge cases are identified: §3 covers denial, offline/dependency failures, replay/body mismatch, stale/races, invalid transitions and signature/duty failures; excluded vendor/override journeys have objective N/A reasons.
- [x] CHK011 Scope is clearly bounded: §§0–1, 4 and 7 preserve 3 safety FRs + 1 administrative slice, exactly 19 NFRs and 7 operations; exclusions include all Feature 012 execution.
- [x] CHK012 Dependencies and assumptions identified: §1 records predecessor integration, existing authority, synthetic-only assumptions and unresolved policy; §§13–14 retain gates.

## Feature Readiness

- [x] CHK013 All functional requirements have complete acceptance criteria: FR mappings exist, but Q1–Q3 prevent claiming final transition, authority and effective-version coverage.
- [x] CHK014 User scenarios cover primary flows: J-01 reporting, J-02 provenance-preserving verification, J-03 independent publication, J-04 unavailable/ineligible status.
- [x] CHK015 Required feature behavior aligns with measurable outcomes: §4 maps to AC-01–16 and SC-001–07. This checks specification alignment, not actual achievement.
- [x] CHK016 No implementation details leak into the specification: canonical names/paths and inherited constraints are references; no DDL, payload design, new endpoint or deployment mechanism is supplied.

## Notes

**Result: DRAFT — 12/16 criteria satisfied; 4 remain open because Q1–Q3 are unresolved. Not ready for `SPEC_APPROVED` or Plan.**

Specific unresolved evidence from the spec:

| Question | Relevant statement | Quality impact | Required resolution |
|---|---|---|---|
| Q1 — allergy policy | §5: “Q1 must define initial states and every allowed edge, actor, reason and guard before approval” | CHK005/006/009/013; AC-01–02 | Product/clinical decision on reporting actors, initial/transition/correction policy and required/unknown fields within the existing operations |
| Q2 — governance/status authority | §7: “Q2 must settle clinic status use without assumed catalog expansion” | CHK005/006/009/013; AC-05–06/09 | Existing credential/role/action mapping and authorized clinic status projection; reconcile any canonical change before dependent planning |
| Q3 — release policy | §14: “No medical vocabulary, source list, expiry threshold, automatic activation schedule or rollback endpoint is selected” | CHK005/006/009/013; AC-04/08/13 | Approved category/source/evidence and effective-date/precedence/replacement/rollback policy within seven operations |

No additional draft-quality defect was identified in the documentation guard review. The unresolved items are intentionally retained for the next authorized `$speckit-clarify` turn; this turn does not ask or answer them. Clinical owners must separately approve real content. `OPEN-CLIN-001`, `OPEN-TECH-002/003`, `OPEN-UX-001/002` and applicable `OPEN-LEGAL-001/002/007` stay open with their stated effects. No implementation test, canonical verification, live acceptance, external approval, commit, push or PR result is claimed.

## Traceability and scope review

- Target FR set: `FR-SAFE-002`, `FR-SAFE-008`, `FR-SAFE-012`, clinical-content publication slice of `FR-ADMIN-004` only.
- Target NFR set: exact roadmap CORE (18) plus `NFR-PRIV-001` (1), with explicit obligations in spec §4.
- Operation set: `listAllergies`, `createAllergy`, `verifyAllergy`, `listClinicalContent`, `createClinicalContentRelease`, `signClinicalContentRelease`, `publishClinicalContentRelease`; no additions.
- Approval status: `DRAFT`; specification Product Owner/domain review pending. Unchecked legal/approval obligations in §§2/13 are not failed engineering tests and are not legal evidence.

## Workflow and review evidence

The installed `speckit-specify` v1.0.13 integration and SHIFAA overlays were used. The first-priority template resolved from `.specify/templates/overrides/spec-template.md`; this checklist follows the Specify quality criteria and the resolved checklist override's evidence/ownership conventions. `.specify/feature.json` points to this one feature directory.

The extension registry contains no `before_specify` hook and no mandatory `after_specify` hook. Its optional `agent-context` hook (`speckit.agent-context.update`, refresh agent context after specification) was inspected and left unexecuted; no agent-context change was required for the authorized draft. No later lifecycle phase was started.

Draft review on 2026-10-01 checked the FR/NFR/operation sets against the roadmap/current PRD/catalog, four allergy states, all template headings, three clarification markers, AC references, local source links, retained gates and intended changed-file boundary. These are document checks, not runtime or clinical evidence.
